| Date Filed | Type | Description |
| 08/24/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/07/2023 |
8-K
| Other Events Interactive Data |
| 08/03/2023 |
8-K
| Investor presentation, Quarterly results |
| 06/28/2023 |
4
| Kuhlmann Shirley R. (EVP and General Counsel) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Sold 16,621 shares
@ $21.6544, valued at
$359.9k
Sold 1,363 shares
@ $22.5349, valued at
$30.7k
|
|
| 06/02/2023 |
4
| Ciaffoni Joseph (President and CEO) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Sold 31,272 shares
@ $22.0887, valued at
$690.8k
Sold 30,272 shares
@ $21.5768, valued at
$653.2k
Sold 1,000 shares
@ $22.2511, valued at
$22.3k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
4
| Ciaffoni Joseph (President and CEO) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Sold 31,271 shares
@ $21.9023, valued at
$684.9k
Sold 31,272 shares
@ $21.8661, valued at
$683.8k
|
|
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
4
| Balice-Gordon Rita J. (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| McFarlane Neil F. (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| Heffernan Michael Thomas (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| Freund John Gordon (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| Fallon John A. (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| Melincoff Gwen A (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| SANTINI GINO (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
4
| BOHLIN GAREN G (Director) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 9,792 shares
@ $0 |
|
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Investor presentation, Quarterly results |
| 03/17/2023 |
4
| Tupper Colleen (EVP & CFO) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Sold 31,640 shares
@ $23.7726, valued at
$752.2k
|
|
| 03/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
4
| Smith Thomas B (EVP and Chief Medical Officer) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 31,185 shares
@ $0 |
|
| 02/14/2023 |
4
| Kuhlmann Shirley R. (EVP and General Counsel) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 48,125 shares
@ $0
Granted 25,739 shares
@ $0
Paid exercise price by delivering 16,291 shares
@ $26.75, valued at
$435.8k
Paid exercise price by delivering 7,755 shares
@ $26.75, valued at
$207.4k
Sold 21,811 shares
@ $26.88, valued at
$586.3k
|
|
| 02/14/2023 |
4
| Tupper Colleen (EVP & CFO) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 45,045 shares
@ $0
Granted 12,565 shares
@ $0
Paid exercise price by delivering 6,967 shares
@ $26.75, valued at
$186.4k
Paid exercise price by delivering 3,887 shares
@ $26.75, valued at
$104k
|
|
| 02/14/2023 |
4
| Ciaffoni Joseph (President and CEO) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 117,500 shares
@ $0
Granted 137,694 shares
@ $0
Paid exercise price by delivering 44,121 shares
@ $26.75, valued at
$1.2M
Paid exercise price by delivering 59,736 shares
@ $26.75, valued at
$1.6M
Sold 11,250 shares
@ $26.88, valued at
$302.4k
Exercised 11,250 options to buy
@ $15.9, valued at
$178.9k
|
|
| 02/14/2023 |
4
| Dreyer Scott (EVP & Chief Commercial Officer) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC|
Txns:
| Granted 44,275 shares
@ $0
Granted 22,459 shares
@ $0
Paid exercise price by delivering 14,529 shares
@ $26.75, valued at
$388.7k
Paid exercise price by delivering 6,797 shares
@ $26.75, valued at
$181.8k
|
|
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.6% stake in Collegium Pharmaceutical Inc. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|